The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 19, 2026
Filed:
May. 20, 2021
Takeda Pharmaceutical Company Limited, Osaka, JP;
Tomoaki Hasui, Fujisawa, JP;
Satoshi Mikami, Fujisawa, JP;
Toru Yamashita, Fujisawa, JP;
Shinji Nakamura, Fujisawa, JP;
Shinji Morimoto, Fujisawa, JP;
Toshihiro Imaeda, Fujisawa, JP;
Kazuaki Takami, Fujisawa, JP;
Masaki Daini, Fujisawa, JP;
Hiroyuki Kakei, Fujisawa, JP;
Minoru Nakamura, Fujisawa, JP;
Fumie Yamaguchi, Fujisawa, JP;
Chunxiang Wang, Fujisawa, JP;
Sachie Takashima, Fujisawa, JP;
Shogo Hashizume, Fujisawa, JP;
Takeda Pharmaceutical Company Limited, Osaka, JP;
Abstract
The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 100 to page 143; examples 1 to 167; test examples 1 and 2; tables 1 to 4).